vimarsana.com

Latest Breaking News On - Stefan quenneville - Page 1 : vimarsana.com

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his “Buy” rating on Nova Leap Health.

United statesChris dobbinStefan quennevilleNova leap health stockUnitedhealth group incEchelon capital marketsNova leap healthNova leap health stock quoteNova leapUnitedhealth group

NSCI stock is undervalued, Echelon says

Following the release of preliminary fourth quarter results, Echelon analyst Stefan Quenneville remains bullish about Nanalysis Scientific.

Stefan quennevilleSean krakiwskyNanalysis scientificNanalysis scientific stock quote

VPH stock has price target lowered at Echelon

Following the company’s fourth quarter results, Echelon Capital Markets analyst Stefan Quenneville has lowered his price target on Valeo Pharma

Valeo pharmaStefan quennevilleSteve saviukEchelon capital marketsValeo pharma stock quote

Tuesday s analyst upgrades and downgrades - The Globe and Mail

Inside the Market’s roundup of some of today’s key analyst actions

United statesPoitou charentesBrent stadlerRaymond jame farooq hamedBrent watsonSabahat khanStefan quennevilleStifel tom stephanCanaccord genuity katie lachapelleCiti joanne wuenschLinda ezergailisJamie kubikDoug youngMorgan michael gambardellaKevin chiangStifel cole pereira

Buy ATE stock for a double, Echelon says

Following the company’s Q2, 2024 interim results, Echelon analyst Stefan Quenneville still thinks there is money to be made on Antibe Therapeutics

Dan legaultStefan quennevilleEchelon capital marketsAntibe therapeuticsAntibe therapeutics stock quoteSpeculative buy

vimarsana © 2020. All Rights Reserved.